Credit Ratings

Boston Scientific stock faces negative outlook as leverage risk rises – ad-hoc

By

S&P Global Ratings — Boston Scientific stock faces negative outlook as leverage risk rises  ad-hoc-news.de

Read the original at S&P Global Ratings ↗

Auto-published by the finit.news Events monitor from S&P Global Ratings; summarized by AI and may contain errors — verify against the primary source. November 10, 2026.

By

Related Post

Credit Ratings

Fitch assigns Uzbekistan’s power grid operator ‘BB’ rating

Credit Ratings

S&P raises GEO Group rating to ’BB+’ on debt reduction and 1x leverage goal

Credit Ratings

Fitch affirms Uzbektelecom at ‘BB’ with Positive Outlook

Financial News For All

Labor

Ohio Print Shop Employees Unionize

Regulatory Approvals

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors

Regulatory Approvals

FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor

Regulatory Approvals

FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor